BofA analyst Tim Anderson raised the firm’s price target on Eli Lilly (LLY) to $1,000 from $997 and keeps a Buy rating on the shares after ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

In a report released yesterday, Mark Lipacis from Evercore ISI maintained a Hold rating on Qualcomm (QCOM – Research Report), with a price ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Stay updated on the latest stock market trends and company earnings. Discover the impact of market gains and profit reports ...

U.S. stock futures are edging mostly higher as market participants focus on tech stocks and corporate earnings; Honeywell announces a split of its automation, aerospace, and advan ...

Minnesota Attorney General Keith Ellison announced on Monday that a settlement has been reached Novo Nordisk over the high ...

Looking at options history for Qualcomm QCOM we detected 23 trades. If we consider the specifics of each trade, it is accurate to state that 39% of the investors opened trades with bullish ...

In this article, we are going to take a look at where QUALCOMM Incorporated (NASDAQ:QCOM) stands against other best socially responsible stocks to buy according to hedge funds. Socially responsible ...

Madison Investments highlighted QCOM in its Q3 2024 investor letter. Here is what the firm has to say: “Alphabet Inc., Eli Lilly and Company, QUALCOMM Incorporated (NASDAQ:QCOM), Microsoft ...

Solbinsiran sodium is under clinical development by Eli Lilly and Co and currently in Phase II for Mixed Dyslipidemia. According to GlobalData, Phase II drugs for Mixed Dyslipidemia have a 74% phase ...